142 related articles for article (PubMed ID: 2158152)
21. Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest).
Bara L; Combe-Tamzali S; Conard J; Horellou MH; Samama M
Haemostasis; 1987; 17(3):127-33. PubMed ID: 3609913
[TBL] [Abstract][Full Text] [Related]
22. A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
Abrial D; Blanc A; Réhailia M; Mismetti P; Bouchut C; Laporte-Simitsidis S; Decousus H; Buisson B
Haemostasis; 2000; 30(5):233-42. PubMed ID: 11251330
[TBL] [Abstract][Full Text] [Related]
23. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.
Stiekema JC; Van Griensven JM; Van Dinther TG; Cohen AF
Br J Clin Pharmacol; 1993 Jul; 36(1):51-6. PubMed ID: 8396956
[TBL] [Abstract][Full Text] [Related]
24. Future alternatives to heparin: low-molecular-weight heparin and hirudin.
Donayre CE; Ouriel K; Rhee RY; Shortell CK
J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932
[TBL] [Abstract][Full Text] [Related]
25. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers.
Hoffmann U; Harenberg J; Bauer K; Huhle G; Tolle AR; Feuring M; Christ M
Blood Coagul Fibrinolysis; 2002 Jun; 13(4):289-96. PubMed ID: 12032393
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
[TBL] [Abstract][Full Text] [Related]
27. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
[TBL] [Abstract][Full Text] [Related]
28. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.
Linhardt RJ; Loganathan D; al-Hakim A; Wang HM; Walenga JM; Hoppensteadt D; Fareed J
J Med Chem; 1990 Jun; 33(6):1639-45. PubMed ID: 2160537
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of low-molecular-weight heparins in cardiovascular disease.
Abbate R; Gori AM; Farsi A; Attanasio M; Pepe G
Am J Cardiol; 1998 Sep; 82(5B):33L-36L. PubMed ID: 9737479
[TBL] [Abstract][Full Text] [Related]
30. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
Kitchen S; Iampietro R; Woolley AM; Preston FE
Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
[TBL] [Abstract][Full Text] [Related]
31. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
[TBL] [Abstract][Full Text] [Related]
32. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
Hellstern P; Bach J; Simon M; Saggau W
J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
[TBL] [Abstract][Full Text] [Related]
33. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin.
Jeske WP; Hoppensteadt D; Gray A; Walenga JM; Cunanan J; Myers L; Fareed J; Bayol A; Rigal H; Viskov C
Thromb Res; 2011 Oct; 128(4):361-7. PubMed ID: 21458847
[TBL] [Abstract][Full Text] [Related]
34. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides.
Raake W; Klauser RJ; Elling H; Meinetsberger E
Thromb Res; 1989 Dec; 56(6):719-30. PubMed ID: 2561233
[TBL] [Abstract][Full Text] [Related]
35. The establishment and validation of efficient assays for anti-IIa and anti-Xa activities of heparin sodium and heparin calcium.
Suzuki T; Ishii-Watabe A; Hashii N; Nakagawa Y; Takahashi T; Ebisawa A; Nishi S; Fujita N; Bando A; Sekimoto Y; Miyata K; Endo T; Otsu T; Sugimoto S; Kondou T; Fujita Y; Miyanaga N; Mashimo M; Shimada N; Yoden H; Shimamura H; Kurata Y; Koyama S; Kawasaki N
Biologicals; 2013 Nov; 41(6):415-23. PubMed ID: 24095600
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
[TBL] [Abstract][Full Text] [Related]
37. Laboratory monitoring of the clinical effects of low molecular weight heparins.
Walenga JM; Hoppensteadt D; Fareed J
Thromb Res Suppl; 1991; 14():49-62. PubMed ID: 1658970
[TBL] [Abstract][Full Text] [Related]
38. HEPTEST: a suitable method for monitoring heparin during pregnancy.
Campbell PJ; Tirvengadum MA; Pickering W; Cohen H; Ryan KE
Clin Lab Haematol; 1999 Jun; 21(3):193-9. PubMed ID: 10448601
[TBL] [Abstract][Full Text] [Related]
39. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.
Tobu M; Iqbal O; Hoppensteadt D; Neville B; Messmore HL; Fareed J
Clin Appl Thromb Hemost; 2004 Oct; 10(4):301-9. PubMed ID: 15497016
[TBL] [Abstract][Full Text] [Related]
40. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
